Zhang Lifeng, Yang Hui, Zhang Xinmei, Chen Zhengyun
Department of Gynecology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Hunan Maternal and Child Health Hospital, Changsha 410008, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019 Apr 25;48(2):130-135. doi: 10.3785/j.issn.1008-9292.2019.04.02.
To evaluate the efficacy and adverse effects of levonorgestrel-releasing intrauterine system (Mirena) in the treatment of adenomyosis.
The clinical data of 75 patients with adenomyosis who had Mirena insertion in Women's Hospital,Zhejiang University School of Medicine from September 2013 to December 2013 were retrospectively analyzed. The patients were followed up to 39 months. The efficacy and adverse effects were assessed.
Pictorial Blood Loss Assessment Chart (PBAC) scores were decreased significantly after Mirena insertion both in patients with menorrhea (118±13 vs. 29±33, <0.01) and normal menstruation (82±15 vs. 14±13, <0.01); the patients with menorrhea showed a more significant decrease in PBAC score than those with normal menstruation (90±35 vs. 69±19,<0.01). The visual analogue scale (VAS) score decreased significantly after Mirena insertion compared with pre-treatment[7(6,7) vs. 1(0,2), <0.01]. The expulsion of Mirena occurred in 18 cases (24.0%); 9 cases (12.0%) had no effect and 28 cases (37.3%) had changes of menstruation patterns. Multivariate Cox regression analysis showed that the expulsion of Mirena was not associated with post-treatment VAS score, PBAC score before and after treatment or menstrual stabilization time (all >0.05).
Mirena is effective and safe in the long term management of adenomyosis, but about one third patients may require further treatment because of the expulsion or ineffectiveness of Mirena.
评估左炔诺孕酮宫内节育系统(曼月乐)治疗子宫腺肌病的疗效及不良反应。
回顾性分析2013年9月至2013年12月在浙江大学医学院附属妇产科医院放置曼月乐的75例子宫腺肌病患者的临床资料。对患者进行了长达39个月的随访,评估疗效及不良反应。
放置曼月乐后,月经过多患者的图像失血评估图(PBAC)评分显著降低(118±13 vs. 29±33,<0.01),月经正常患者的PBAC评分也显著降低(82±15 vs. 14±13,<0.01);月经过多患者的PBAC评分下降幅度大于月经正常患者(90±35 vs. 69±19,<0.01)。与治疗前相比,放置曼月乐后视觉模拟评分法(VAS)评分显著降低[7(6,7) vs. 1(0,2),<0.01]。曼月乐脱落18例(24.0%);9例(12.0%)无效,28例(37.3%)月经模式改变。多因素Cox回归分析显示,曼月乐脱落与治疗后VAS评分、治疗前后PBAC评分或月经稳定时间均无关(均>0.05)。
曼月乐在子宫腺肌病的长期管理中有效且安全,但约三分之一的患者可能因曼月乐脱落或无效而需要进一步治疗。